Gina Consylman Net Worth

The estimated Net Worth of Gina Consylman is at least $5.56 Million dollars as of 26 February 2021. Ms. Consylman owns over 18,406 units of Ironwood Pharmaceuticals Inc stock worth over $1,462,661 and over the last 10 years she sold IRWD stock worth over $645,719. In addition, she makes $3,453,580 as Chief Financial Officer and Senior Vice President at Ironwood Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Consylman IRWD stock SEC Form 4 insiders trading

Gina has made over 16 trades of the Ironwood Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she sold 18,406 units of IRWD stock worth $167,679 on 26 February 2021.

The largest trade she's ever made was selling 18,406 units of Ironwood Pharmaceuticals Inc stock on 26 February 2021 worth over $167,679. On average, Gina trades about 1,385 units every 46 days since 2014. As of 26 February 2021 she still owns at least 336,244 units of Ironwood Pharmaceuticals Inc stock.

You can see the complete history of Ms. Consylman stock trades at the bottom of the page.

Gina Consylman biography

Gina Consylman CPA serves as Chief Financial Officer, Senior Vice President of the Company. She has served as our senior vice president, chief financial officer since November 2017. Ms. Consylman previously served as our interim Chief Financial Officer from September 2017 to November 2017, and as our Vice President of Finance and Chief Accounting Officer from August 2015 to November 2017. She also previously served as our Vice President, Corporate Controller and Chief Accounting Officer from June 2014 to July 2015. Ms. Consylman currently serves on the Board of Directors of Verastem Oncology. Prior to joining Ironwood, Ms. Consylman served as Vice President, Corporate Controller and Principal Accounting Officer of Analogic Corporation (which was acquired by funds affiliated with Altaris Capital Partners, LLC), a publicly held healthcare and security technology solutions company, from February 2012 to June 2014, where she oversaw Analogic’s global accounting team. Prior to joining Analogic, Ms. Consylman served in various corporate accounting roles at Biogen Inc., a publicly held global biotechnology company, from November 2009 to February 2012, culminating in her service as Senior Director, Corporate Accounting where she was responsible for the accounting teams for the corporate and U.S. commercial business units. Ms. Consylman has also served in various other finance and accounting roles, including Corporate Controller at Varian Semiconductor Equipment Associates, Inc. (subsequently acquired by Applied Materials, Inc.). Ms. Consylman, a Certified Public Accountant, began her career in public accounting at Ernst & Young LLP. She holds a B.S. in accounting from Johnson & Wales University and a M.S. in taxation from Bentley University.

What is the salary of Gina Consylman?

As the Chief Financial Officer and Senior Vice President of Ironwood Pharmaceuticals Inc, the total compensation of Gina Consylman at Ironwood Pharmaceuticals Inc is $3,453,580. There are 3 executives at Ironwood Pharmaceuticals Inc getting paid more, with Mark Mallon having the highest compensation of $10,068,800.

How old is Gina Consylman?

Gina Consylman is 48, she's been the Chief Financial Officer and Senior Vice President of Ironwood Pharmaceuticals Inc since 2017. There are 17 older and 2 younger executives at Ironwood Pharmaceuticals Inc. The oldest executive at Ironwood Pharmaceuticals Inc is Edward Owens, 73, who is the Independent Director.

What's Gina Consylman's mailing address?

Gina's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., TWO TOWER PLACE, 7TH FLOOR, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Ironwood Pharmaceuticals Inc

Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over $83,928,361 worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth $24,100,589 . The most active insiders traders include Llc Fmr, Bryan E Roberts, and Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $239,611. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth $42,316.

What does Ironwood Pharmaceuticals Inc do?

ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b

Complete history of Ms. Consylman stock trades at Assembly Biosciences Inc, Bluebird bio Inc, Ironwood Pharmaceuticals Inc, and Verastem Inc

Ironwood Pharmaceuticals Inc executives and stock owners

Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mark Mallon,
  Chief Executive Officer, Director
• Thomas McCourt,
  President
• Mark Currie,
  Director
• Gina Consylman,
  Chief Financial Officer, Senior Vice President
• Thomas A. McCourt,
  CEO & Director
• Jason Rickard,
  COO & Sr. VP of Operations
• Dr. Michael Shetzline M.D., Ph.D.,
  Chief Medical Officer, Sr. VP and Head of R&D
• Catherine Moukheibir,
  Independent Director
• Jon Duane,
  Independent Director
• Marla Kessler,
  Independent Director
• Julie McHugh,
  Independent Chairman of the Board
• Andrew Dreyfus,
  Independent Director
• Edward Owens,
  Independent Director
• Lawrence Olanoff,
  Independent Director
• Julie H. McHugh,
  Exec. Chairman
• Alexander Denner,
  Director
• Meredith Kaya,
  Vice President - Investor Relations and Corporate Communications
• Michael Shetzline,
  Chief Medical Officer, Senior Vice President and Head of Drug Development
• Conor Kilroy,
  Senior Vice President, General Counsel
• Jason Rickard,
  Chief Operating Officer, Senior Vice President
• John Minardo,
  Sr. VP & Chief Legal Officer
• Marcel Moulaison,
  VP of Technical Operations
• Ronald Silver,
  Corp. Controller & Principal Accounting Officer
• Sravan Kumar Emany,
  Sr. VP & CFO
• G. Todd Milne,
  Co-Founder and VP of sGC R&D
• Brian M. Cali,
  Co-Founder and Sr. VP of R&D Strategy & External Innovation
• Terrance Mcguire,
  Director
• Douglas E Williams,
  Director
• Amy W Schulman,
  Director
• Marsha Fanucci,
  Director
• Christopher T Phd Walsh,
  Director
• Peter M Hecht,
  Chief Executive Officer
• Thomas Graney,
  Chief Financial Officer
• William Huyett,
  Chief Operating Officer
• Halley E Gilbert,
  Chief Admin Officer & SVP
• Bryan E Roberts,
  Director
• Associatesvenrock Associate...,
  
• Management Llc Vr,
  10% owner
• Llc Fmr,
  10% owner
• Llcfil Ltd Fmr,
  
• Co Investment Holdings, Llc...,
  
• Capital Investments L.P.Rid...,
  
• Joseph C Jr Cook,
  Director
• George H Conrades,
  Director
• David Evans Shaw,
  Director
• David A Ebersman,
  Director
• Michael J Higgins,
  Chief Operating Officer
• Kelly Mac Donald,
  Chief Accounting Officer
• Jay Shepard,
  
• Sravan Kumar Emany,
  SVP, Chief Financial Officer
• Alexander J Sarissa Capital...,
  
• Andrew Davis,
  SVP, Chief Business Officer
• Ronald Silver,
  Principal Accounting Officer
• Minardo John,
  Chief Legal Officer